On January 6, 2020 the board of directors of Akers Biosciences, Inc. appointed Howard R. Yeaton as interim Chief Financial Officer of the company. In connection with his appointment as interim Chief Financial Officer of the company, the company and Mr. Yeaton entered into an offer of employment, dated January 6, 2020 (the "Employment Agreement") for a period of ninety days.